John E. Tavis

5.1k total citations
113 papers, 3.5k citations indexed

About

John E. Tavis is a scholar working on Epidemiology, Hepatology and Infectious Diseases. According to data from OpenAlex, John E. Tavis has authored 113 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 90 papers in Epidemiology, 74 papers in Hepatology and 49 papers in Infectious Diseases. Recurrent topics in John E. Tavis's work include Hepatitis B Virus Studies (80 papers), Hepatitis C virus research (72 papers) and HIV/AIDS drug development and treatment (22 papers). John E. Tavis is often cited by papers focused on Hepatitis B Virus Studies (80 papers), Hepatitis C virus research (72 papers) and HIV/AIDS drug development and treatment (22 papers). John E. Tavis collaborates with scholars based in United States, Spain and China. John E. Tavis's co-authors include Feng Cao, D Ganem, Don Ganem, Ermei Yao, Elena Lomonosova, Maureen J. Donlin, Silvia Perri, Volker Bruss, Rajeev Aurora and Xiaohong Cheng and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

John E. Tavis

111 papers receiving 3.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John E. Tavis United States 33 2.4k 2.0k 962 582 346 113 3.5k
Brent E. Korba United States 37 2.7k 1.1× 2.0k 1.0× 1.3k 1.3× 951 1.6× 323 0.9× 113 4.0k
Klaus Klumpp United States 40 2.3k 0.9× 1.7k 0.9× 1.5k 1.6× 1.2k 2.1× 493 1.4× 94 3.9k
Johnson Y. N. Lau United States 38 3.4k 1.4× 3.9k 1.9× 1.1k 1.1× 1.0k 1.8× 311 0.9× 96 5.7k
Timothy L. Tellinghuisen United States 21 2.7k 1.1× 3.3k 1.6× 687 0.7× 1.1k 1.9× 501 1.4× 29 4.5k
O. Hantz France 27 2.4k 1.0× 1.8k 0.9× 672 0.7× 807 1.4× 293 0.8× 90 3.1k
Alexander A. Kolykhalov United States 21 2.4k 1.0× 2.6k 1.3× 1.3k 1.4× 904 1.6× 375 1.1× 42 4.1k
Chao Lin United States 23 2.2k 0.9× 3.2k 1.6× 1.3k 1.3× 1.0k 1.8× 343 1.0× 39 4.3k
Mike Flint United States 35 1.8k 0.7× 2.0k 1.0× 1.2k 1.2× 679 1.2× 331 1.0× 56 4.0k
Ann D. Kwong United States 37 3.8k 1.6× 3.6k 1.8× 1.9k 2.0× 1.9k 3.2× 396 1.1× 70 6.6k
Gilles Duverlie France 33 2.1k 0.9× 2.6k 1.3× 786 0.8× 541 0.9× 332 1.0× 111 4.0k

Countries citing papers authored by John E. Tavis

Since Specialization
Citations

This map shows the geographic impact of John E. Tavis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John E. Tavis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John E. Tavis more than expected).

Fields of papers citing papers by John E. Tavis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John E. Tavis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John E. Tavis. The network helps show where John E. Tavis may publish in the future.

Co-authorship network of co-authors of John E. Tavis

This figure shows the co-authorship network connecting the top 25 collaborators of John E. Tavis. A scholar is included among the top collaborators of John E. Tavis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John E. Tavis. John E. Tavis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Walden, Helen, et al.. (2025). Discovery of N-Hydroxypyridinedione-Based Inhibitors of HBV RNase H: Design, Synthesis, and Extended SAR Studies. International Journal of Molecular Sciences. 26(20). 10239–10239.
3.
Bradley, Daniel P., Qilan Li, Marvin J. Meyers, et al.. (2025). Discovery of bimodal hepatitis B virus ribonuclease H and capsid assembly inhibitors. PLoS Pathogens. 21(2). e1012920–e1012920. 1 indexed citations
4.
Cohen, Chari, Thomas Tu, Philippa C. Matthews, et al.. (2025). Patient and public health perspectives to inform expansion of hepatitis B treatment guidelines. ˜The œLancet. Gastroenterology & hepatology. 10(10). 952–962. 3 indexed citations
5.
Walden, Heather S., et al.. (2024). Efficacy and in vitro pharmacological assessment of novel N -hydroxypyridinediones as hepatitis B virus ribonuclease H inhibitors. Antimicrobial Agents and Chemotherapy. 69(1). e0145524–e0145524. 1 indexed citations
6.
Tu, Thomas, Jochen M. Wettengel, Yuchen Xia, et al.. (2024). Major open questions in the hepatitis B and D field – Proceedings of the inaugural International emerging hepatitis B and hepatitis D researchers workshop. Virology. 595. 110089–110089. 1 indexed citations
7.
Mottaleb, M. Abdul, et al.. (2023). In vitro evaluation of tropolone absorption, metabolism, and clearance. Antiviral Research. 220. 105762–105762. 2 indexed citations
8.
Boettler, Tobias, Upkar S. Gill, Lena Allweiss, et al.. (2022). Assessing immunological and virological responses in the liver: Implications for the cure of chronic hepatitis B virus infection. JHEP Reports. 4(6). 100480–100480. 10 indexed citations
9.
Lin, Jeffrey, Subir Kumar Sadhukhan, Daniel P. Bradley, et al.. (2021). Synthetic Derivatives of Ciclopirox are Effective Inhibitors ofCryptococcus neoformans. ACS Omega. 6(12). 8477–8487. 14 indexed citations
10.
Kong, Ling, Lynn E. Taylor, Kenneth H. Mayer, et al.. (2020). Diversity of the hepatitis C virus NS5B gene during HIV co-infection. PLoS ONE. 15(8). e0237162–e0237162. 5 indexed citations
11.
Li, Qilan, Elena Lomonosova, Maureen J. Donlin, et al.. (2020). Amide-containing α-hydroxytropolones as inhibitors of hepatitis B virus replication. Antiviral Research. 177. 104777–104777. 20 indexed citations
12.
Li, Qilan, et al.. (2019). Divergent synthesis of a thiolate-based α-hydroxytropolone library with a dynamic bioactivity profile. RSC Advances. 9(59). 34227–34234. 10 indexed citations
13.
Cao, Feng, Maureen J. Donlin, Patrick A. Adegboyega, et al.. (2018). Synthesis and Evaluation of Troponoids as a New Class of Antibiotics. ACS Omega. 3(11). 15125–15133. 21 indexed citations
14.
Lomonosova, Elena, et al.. (2017). Efficacy and cytotoxicity in cell culture of novel α-hydroxytropolone inhibitors of hepatitis B virus ribonuclease H. Antiviral Research. 144. 164–172. 39 indexed citations
15.
Lara, James, John E. Tavis, Maureen J. Donlin, et al.. (2012). Coordinated evolution among hepatitis C virus genomic sites is coupled to host factors and resistance to interferon. In Silico Biology. 11(5-6). 213–224. 11 indexed citations
16.
Cao, Feng & John E. Tavis. (2011). RNA Elements Directing Translation of the Duck Hepatitis B Virus Polymerase via Ribosomal Shunting. Journal of Virology. 85(13). 6343–6352. 21 indexed citations
17.
Donlin, Maureen J., Nathan A. Cannon, Rajeev Aurora, et al.. (2010). Contribution of Genome-Wide HCV Genetic Differences to Outcome of Interferon-Based Therapy in Caucasian American and African American Patients. PLoS ONE. 5(2). e9032–e9032. 29 indexed citations
18.
Zhou, Dong‐Hui, et al.. (2007). Separation of near full-length hepatitis C virus quasispecies variants from a complex population. Journal of Virological Methods. 141(2). 220–224. 10 indexed citations
19.
Zhang, Zhian & John E. Tavis. (2006). The Duck Hepatitis B Virus Reverse Transcriptase Functions as a Full-length Monomer. Journal of Biological Chemistry. 281(47). 35794–35801. 15 indexed citations
20.
Sen, Nandini, Feng Cao, & John E. Tavis. (2004). Translation of Duck Hepatitis B Virus Reverse Transcriptase by Ribosomal Shunting. Journal of Virology. 78(21). 11751–11757. 28 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brent E. Korba Breakdown of academic impact, for papers by Klaus Klumpp Breakdown of academic impact, for papers by Johnson Y. N. Lau Breakdown of academic impact, for papers by Timothy L. Tellinghuisen Breakdown of academic impact, for papers by O. Hantz Breakdown of academic impact, for papers by Alexander A. Kolykhalov Breakdown of academic impact, for papers by Chao Lin Breakdown of academic impact, for papers by Mike Flint Breakdown of academic impact, for papers by Ann D. Kwong Breakdown of academic impact, for papers by Gilles Duverlie
Rankless by CCL
2026